Company Overview and News

4
Core Biotech Buys #16: Taking Advantage Of Weakness To Add To Conviction Ideas

2018-05-22 seekingalpha
My ¨Week in Review¨ blog post appears to have the makings of a permanent feature due to positive feedback received thus far.

 
CEOs, Directors and Other Senior Executives Tapped by Biotech

2018-05-22 biospace
Pharma and biotech companies across the globe continued to expand and reshape their leadership teams with new hires this past week. BioSpace collected several announced leadership appointments, which includes new chief executive officers, new members to boards of directors and more.

4
Cellectis: Will Focus On Universal CAR-T Payoff?

2018-05-21 seekingalpha
I believe gene therapy will become a mainstay in treating, and maybe curing, many of our most devastating and intractable illnesses. Scott Gottlieb, FDA Commissioner

 
Your Daily Pharma Scoop: Abeona Presents Strong Data, Glaxo Nucala Treatment Benefit, Rocket Pharma's Gene Therapy Data

2018-05-21 seekingalpha
Rocket Pharma’s gene therapy drug RP-L102 showed treatment benefit in an early stage study in Fanconi anemia.

3
BLNK / Blink Charging Co. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-05-18 fintel.io
Blink Charging Co. (NASDAQ:BLNK) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include . Blink Charging Co. (NASDAQ:BLNK) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions.

1
SLDB / Solid Biosciences Inc - Stock Institutional Ownership and Shareholders - Fintel.io

2018-05-18 fintel.io
Solid Biosciences Inc (NASDAQ:SLDB) has 56 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 19,854,661 shares. Largest shareholders include Perceptive Advisors Llc, JP Morgan Chase & Co, RA Capital Management, LLC, Boxer Capital, LLC, Bain Capital Life Sciences Investors, Llc, BlackRock Inc.

 
MCBP / Michigan Community Bancorp Ltd. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-05-18 fintel.io
Michigan Community Bancorp Ltd. (OTC:MCBP) has 1 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 233,667 shares. Largest shareholders include Marques David Michael. Michigan Community Bancorp Ltd. (OTC:MCBP) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size.

 
Abeona Therapeutics Provides Clinical Update on MPS IIIA Gene Therapy Trial at the 21st Annual ASGCT Meeting

2018-05-18 globenewswire
NEW YORK and CLEVELAND, May 18, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening, rare genetic diseases, announced today updated clinical data from the Phase 1/2 trial for ABO-102 (AAV-SGSH), the company’s clinical gene therapy for the treatment of Sanfilippo syndrome type A (MPS III A) during the 21st Annual Meeting of the ASGCT (American Society for Gene and Cell Therapy) in Chicago, IL.

 
CQPTY / Collplant Holdings Ltd - Stock Institutional Ownership and Shareholders - Fintel.io

2018-05-18 fintel.io
Collplant Holdings Ltd (OTC:CQPTY) has 1 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 29,647,110 shares. Largest shareholders include Sagi Ami. Collplant Holdings Ltd (OTC:CQPTY) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size.

1
EVLO / Evelo Biosciences, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-05-18 fintel.io
Evelo Biosciences, Inc. (NASDAQ:EVLO) has 1 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 379,501 shares. Largest shareholders include Dementia Discovery Lp. Evelo Biosciences, Inc. (NASDAQ:EVLO) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size.

 
GLAG / Gala Global Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-05-17 fintel.io
Gala Global Inc. (OTC:GLAG) has 1 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 5,258,248 shares. Largest shareholders include St George Investments LLC. Gala Global Inc. (OTC:GLAG) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size.

 
ICOX / Appcoin Innovations Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-05-17 fintel.io
Appcoin Innovations Inc. (OTC:ICOX) has 1 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 1,900,000 shares. Largest shareholders include Geiskopf James P. Appcoin Innovations Inc. (OTC:ICOX) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size.

 
NBY / NovaBay Pharmaceuticals, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-05-17 fintel.io
NovaBay Pharmaceuticals, Inc. (AMEX:NBY) has 10 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 1,828,053 shares. Largest shareholders include Op Financial Ltd, Bank Of America Corp /de/, Vanguard Group Inc, BlackRock Inc., Nvwm, Llc, UBS Group AG, Morgan Stanley, Genovese Burford & Brothers Wealth & Retirement Plan Management, LLC, and Royal Bank Of Canada.

 
VBFC / Village Bank & Trust Financial Corp. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-05-17 fintel.io
Village Bank & Trust Financial Corp. (NASDAQ:VBFC) has 15 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 713,523 shares. Largest shareholders include Lehman Kenneth R, Pnc Financial Services Group, Inc., Banc Funds Co Llc, Minerva Advisors LLC, Geode Capital Management, Llc, River Oaks Capital LLC, UBS Group AG, Deutsche Bank Ag\, Morgan Stanley, and Bessemer Group Inc.

 
WPZ / Access Midstream Partners, L.P - Stock Institutional Ownership and Shareholders - Fintel.io

2018-05-17 fintel.io
Access Midstream Partners, L.P (NYSE:WPZ) has 484 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 949,304,658 shares. Largest shareholders include Williams Companies Inc, FMR LLC / Fidelity, Harvest Fund Advisors LLC, Alps Advisors Inc, Tortoise Capital Advisors, L.l.c., Goldman Sachs Group Inc, Kayne Anderson Capital Advisors Lp, Atlantic Trust Group, LLC, Morgan Stanley, and UBS Group AG.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

CUSIP: 00289Y115